Prostate Cancer Trial, Recruiting NCT07535541 Sponsor: University of Virginia Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07535541
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to sign and date a consent form agreeing to take part
  • People who are willing to follow all study procedures and are available for the full duration of the study
  • People who are male (biological sex) and aged 18 or older
  • People who have been diagnosed with prostate cancer
  • People who are currently receiving androgen deprivation therapy (ADT) — a treatment that uses medicine or surgery to lower testosterone levels in the body to treat prostate cancer
  • People whose testosterone levels have been reduced to a very low level as a result of ADT, confirmed by either a blood test result or a pattern of falling PSA (a prostate cancer marker) without signs of it rising again (confirm with trial site)
  • People whose ADT treatment is expected to continue for at least 4 weeks from the time of joining the study
  • People who experience hot flushes or night sweats (known as vasomotor symptoms) that started after beginning ADT and happen at least once a day
  • People who own a compatible smartphone — either an iPhone 8 or newer running iOS 16.0 or higher, or an Android phone running version 12 or higher — with Bluetooth 5, and who are willing to use mobile data or Wi-Fi and download the Empatica Care app
  • People who can read, speak, and understand English
  • People who are generally well enough to carry out everyday activities, with only mild limitations at most (this is measured on a standard scale called ECOG — confirm with trial site)

Who may not be able to join:

  • People whose wrist measurement is smaller than 95 mm or larger than 222 mm, as the study watch may not fit properly
  • People who have a known skin allergy to silicone, which is a material used in the study smartwatch
  • People who experienced hot flushes or night sweats before they started ADT treatment
  • People who currently have a fever above 38°C or are being treated for a fever-related illness
  • People who are unable to press the button on the side of the study smartwatch
  • People who are currently taking part in another experimental treatment trial for prostate cancer
  • People whose prostate cancer shows signs of progressing or getting worse based on specific measurement criteria (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Devitt, MD, University of Virginia

Phone: 434-421-5577

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 May 2026
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Duration of wear per day; Percent of days with self-reported time marked vasomotor events; Concordance between time marked vasomotor events and events described through EMAs.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov